Cardiac myosin inhibitors: Efficacy, safety and future directions of aficamten in hypertrophic obstructive cardiomyopathy
Abstract Background Hypertrophic obstructive cardiomyopathy (HOCM) is a genetic disorder that affects the cardiac myocytes leading to asymmetric hypertrophy of the left ventricle and obstruction of the left ventricular outflow tract (LVOT) with possible risk of sudden cardiac death in some high-risk...
Saved in:
| Main Authors: | Ikponmwosa Jude Ogieuhi, Victor Oluwatomiwa Ajekiigbe, Boluwaduro Abasiekem Adeyemi, Bright Nwatamole, Komolafe Babajide Ayodeji, Oshomoh Mark-Anthony Ugiomoh, Temiloluwa Adebayo Odeniyi, Adewunmi Akingbola, Efosa Peace Iyawe, Olabode Olawale Oladejo, Motunrayo Oluwatoyosi Lawal, Nathnael Abera Woldehana, Ifeoluwa Sandra Bakare, Adejumo Temilade Patience, Grace Chinenye Okoro |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2025-06-01
|
| Series: | The Egyptian Heart Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43044-025-00652-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy
by: Bryton J. Davis, et al.
Published: (2025-03-01) -
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA‐HCM
by: Caroline J. Coats, et al.
Published: (2024-08-01) -
Comprehensive Review: Mavacamten and Aficamten in Hypertrophic Cardiomyopathy
by: Helin Savsin, et al.
Published: (2025-07-01) -
Obstructive hypertrophic cardiomyopathy: from genetic insights to a multimodal therapeutic approach with mavacamten, aficamten, and beyond
by: Khadija Sarwer, et al.
Published: (2024-12-01) -
The socioeconomic impact of kidney disease on African families: a scoping review
by: Ikponmwosa Jude Ogieuhi, et al.
Published: (2025-01-01)